
Larry Levitt
Articles
-
Dec 5, 2024 |
kff.org | Larry Levitt
In this JAMA Health Forum column, KFF Executive Vice President Larry Levitt explores why the incoming Trump administration and Republican majorities in Congress are likely to pursue budget cuts in Medicaid and the Affordable Care Act and why such efforts are likely to boost the number of uninsured Americans while shifting financial responsibility and decision-making to the states.
-
Sep 5, 2024 |
kff.org | Larry Levitt
With Vice President Harris promising to address medical debt as part of her economic plan, KFF Executive Vice President for Health Policy Larry Levitt explores why it is a symptom of the broader problem of affordable health care and reviews recent efforts to address it in this JAMA Health Forum post.
-
Sep 5, 2024 |
jamanetwork.com | Larry Levitt
Lack of affordability is arguably the biggest challenge in US health care, and the high level of medical debt is a tangible reflection of this challenge. A 2022 KFF survey found that 41% of people had debt due to medical or dental care for themselves or someone else; a related series by KFF’s journalism program, KFF Health News, documented the effect of that debt on people’s lives.
-
Aug 19, 2024 |
kff.org | Tricia Neuman |Juliette Cubanski |Larry Levitt
Authored by KFF’s Tricia Neuman, Juliette Cubanski and Larry Levitt, this post for Health Affairs Forefront examines how the results of the first-ever Medicare drug price negotiations will generate savings for the government and for Medicare beneficiaries, and how candidates’ views on the issue could play a role in the upcoming elections and in shaping the future of government negotiation of drug prices.
-
Aug 19, 2024 |
healthaffairs.org | Tricia Neuman |Juliette Cubanski |Larry Levitt
On August 15, 2024, the Centers for Medicare & Medicaid Services (CMS) announced negotiated prices for the first 10 drugs selected under Medicare’s new Drug Price Negotiation Program, established by the Inflation Reduction Act of 2022. This announcement marked the end of a months-long negotiation process between CMS and the manufacturers of these 10 drugs, with new prices taking effect for Medicare beneficiaries on January 1, 2026.
Try JournoFinder For Free
Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.
Start Your 7-Day Free Trial →